🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the battle against increasingly resistant strains of the infection, according to researchers.

A Global Challenge

Gonorrhoea infections are increasing worldwide, with figures suggesting in excess of 82 million instances each year. Especially elevated rates are reported in the African continent and countries within the WHO's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary development in the context of rising global incidence, escalating drug resistance and the highly restricted treatment choices at this time.”

Health officials are increasingly worried about the surge in drug-resistant strains. The World Health Organization has designated it as a "priority pathogen". Recent surveillance found that the effectiveness of primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Gain Authorization

One new antibiotic, also known as a brand name, was cleared by the US Food and Drug Administration in December for combating gonorrhoea. This infection can lead to major issues, including infertility. Scientists hope that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, also received approval in the same week. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment emerged from a innovative non-profit model for medication research. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to develop it.

“This milestone represents a huge turning point in the therapy of highly resistant gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Clinical Trial Outcomes and Global Access

According to data published in a prominent scientific publication, zoliflodacin successfully treated more than 90% of uncomplicated infections. This puts it on an similar efficacy with the current standard treatment, which involves two antibiotics. The trial involved over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the ability to register and commercialise the drug in numerous regions with limited resources.

Doctors on the front lines have shared optimism. The availability of a one-pill regimen of this kind is hailed as a "game-changer" for gonorrhoea control. This is deemed essential to lessen the impact of the illness for patients and to stop the proliferation of highly drug-resistant gonorrhoea globally.